EP1023295A4 - Promedicaments antagonistes de recepteur de fibrinogene - Google Patents

Promedicaments antagonistes de recepteur de fibrinogene

Info

Publication number
EP1023295A4
EP1023295A4 EP98906092A EP98906092A EP1023295A4 EP 1023295 A4 EP1023295 A4 EP 1023295A4 EP 98906092 A EP98906092 A EP 98906092A EP 98906092 A EP98906092 A EP 98906092A EP 1023295 A4 EP1023295 A4 EP 1023295A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonist
fibrinogen receptor
antagonist prodrugs
prodrugs
fibrinogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98906092A
Other languages
German (de)
English (en)
Other versions
EP1023295A1 (fr
Inventor
Melissa S Egbertson
Steve D Young
George D Hartman
Jacquelynn J Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9707489.2A external-priority patent/GB9707489D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1023295A1 publication Critical patent/EP1023295A1/fr
Publication of EP1023295A4 publication Critical patent/EP1023295A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP98906092A 1997-02-06 1998-02-02 Promedicaments antagonistes de recepteur de fibrinogene Withdrawn EP1023295A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3690197P 1997-02-06 1997-02-06
US36901P 1997-02-06
GB9707489 1997-04-14
GBGB9707489.2A GB9707489D0 (en) 1997-04-14 1997-04-14 Fibrinogen receptor antagonist prodrugs
PCT/US1998/001998 WO1998034935A1 (fr) 1997-02-06 1998-02-02 Promedicaments antagonistes de recepteur de fibrinogene

Publications (2)

Publication Number Publication Date
EP1023295A1 EP1023295A1 (fr) 2000-08-02
EP1023295A4 true EP1023295A4 (fr) 2001-01-24

Family

ID=26311371

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98906092A Withdrawn EP1023295A4 (fr) 1997-02-06 1998-02-02 Promedicaments antagonistes de recepteur de fibrinogene

Country Status (5)

Country Link
EP (1) EP1023295A4 (fr)
JP (1) JP2001512439A (fr)
AU (1) AU747293B2 (fr)
CA (1) CA2279927A1 (fr)
WO (1) WO1998034935A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2263179T3 (es) 1996-06-14 2006-12-01 Biocryst Pharmaceuticals Inc. Compuestos de clopentano sustituido como inhibidores de la neuraminidasa.
JP4102022B2 (ja) 1997-12-17 2008-06-18 バイオクリスト・ファマシューティカルズ インク． ノイラミニダーゼ阻害剤として有用な置換シクロペンタン及びシクロペンテン化合物
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
AU1520300A (en) 1998-11-05 2000-05-29 Biocryst Pharmaceuticals, Inc. New cyclopentane and cyclopentene compounds and use for detecting influenza virus
WO2000075129A1 (fr) * 1999-06-07 2000-12-14 Shire Biochem Inc. Inhibiteurs d'integrine thiophene
ES2394550T3 (es) * 2008-02-21 2013-02-01 Sanofi Clorotiofen-amidas como inhibidores de los factores Xa de coagulación y trombina
CN111943818B (zh) * 2020-09-16 2023-01-24 天津均凯农业科技有限公司 一种制备4,4′-双三氟甲基二苯醚的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008962A1 (fr) * 1992-10-14 1994-04-28 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
WO1994008577A1 (fr) * 1992-10-14 1994-04-28 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
WO1994012181A1 (fr) * 1992-12-01 1994-06-09 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
WO1994018981A1 (fr) * 1993-02-22 1994-09-01 Merck & Co., Inc. Antagonistes des recepteurs de fibrinogene
EP0656348A2 (fr) * 1993-12-03 1995-06-07 F. Hoffmann-La Roche Ag Dérivés d'acide acérique comme médicaments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008962A1 (fr) * 1992-10-14 1994-04-28 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
WO1994008577A1 (fr) * 1992-10-14 1994-04-28 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
WO1994012181A1 (fr) * 1992-12-01 1994-06-09 Merck & Co., Inc. Antagonistes des recepteurs du fibrinogene
WO1994018981A1 (fr) * 1993-02-22 1994-09-01 Merck & Co., Inc. Antagonistes des recepteurs de fibrinogene
EP0656348A2 (fr) * 1993-12-03 1995-06-07 F. Hoffmann-La Roche Ag Dérivés d'acide acérique comme médicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9834935A1 *

Also Published As

Publication number Publication date
JP2001512439A (ja) 2001-08-21
AU6141398A (en) 1998-08-26
WO1998034935A1 (fr) 1998-08-13
EP1023295A1 (fr) 2000-08-02
AU747293B2 (en) 2002-05-16
CA2279927A1 (fr) 1998-08-13

Similar Documents

Publication Publication Date Title
AU3503797A (en) Fibrinogen receptor antagonist prodrugs
EP0912175A4 (fr) Antagonistes du recepteur de fibrinogene
PL348375A1 (en) Pyrrolidine derivatives-ccr-3 receptor antagonists
HU9603525D0 (en) Vironectin receptor antagonists
EP0810994A4 (fr) Antagonistes des recepteurs de fibrinogene
EP1000031A4 (fr) Antagonistes du recepteur de vitronectine
EP0866705A4 (fr) Antagonistes du recepteur de fibrinogene
EP0885205A4 (fr) Antagonistes des recepteurs de fibrinogenes
EP0885213A4 (fr) Antagonistes du recepteur du fibrinogene
EP0796098A4 (fr) Antagonistes des recepteurs du fibrinogene
IL135797A0 (en) Thrombin receptor antagonists
EP0801650A4 (fr) Antagonistes des recepteurs du fibrinogene
EP0929218A4 (fr) Antagonistes des recepteurs p2y
IL134301A0 (en) 2-acylaminopropanamines as tachykinin receptor antagonists
EP0912182A4 (fr) Promedicaments antagonistes du recepteur de fibrinogene
EP0794779A4 (fr) Antagonistes des recepteurs du fibrinogene
EP1023295A4 (fr) Promedicaments antagonistes de recepteur de fibrinogene
EP1084142A4 (fr) Recepteur de gpr35a
GB9515852D0 (en) Fibrinogen receptor antagonists
EP0973800A4 (fr) Nouveau recepteur
IL134155A0 (en) 2-acylaminopropanamines as tachykinin receptor antagonists
GB9819420D0 (en) Novel receptor
EP0800395A4 (fr) Antagonistes des recepteurs du fibrinogene
GB9707489D0 (en) Fibrinogen receptor antagonist prodrugs
EP0781133A4 (fr) Antagonistes du recepteur de fibrinogene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20001212

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 487/00 A, 7C 07D 491/00 B, 7C 07D 495/00 B, 7C 07C 69/02 B, 7C 07D 487/04 B, 7C 07D 209/42 B, 7C 07D 333/38 B, 7C 07C 311/19 B, 7A 61K 31/55 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020301